vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and NEW JERSEY RESOURCES CORP (NJR). Click either name above to swap in a different company.
NEW JERSEY RESOURCES CORP is the larger business by last-quarter revenue ($939.4M vs $708.5M, roughly 1.3× Medpace Holdings, Inc.). NEW JERSEY RESOURCES CORP runs the higher net margin — 23.3% vs 19.1%, a 4.2% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -33.0%). Over the past eight quarters, NEW JERSEY RESOURCES CORP's revenue compounded faster (111.6% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
New Jersey Resources is an energy services holding company based in Wall Township, New Jersey. It is a Fortune 1000 company, and a member of the Forbes Platinum 400. New Jersey Natural Gas is its principal subsidiary.
MEDP vs NJR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $939.4M |
| Net Profit | $135.1M | $218.9M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 32.0% |
| Net Margin | 19.1% | 23.3% |
| Revenue YoY | 32.0% | -33.0% |
| Net Profit YoY | 15.5% | 7.2% |
| EPS (diluted) | $4.65 | $2.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $939.4M | ||
| Q4 25 | $708.5M | $440.9M | ||
| Q3 25 | $659.9M | $188.3M | ||
| Q2 25 | $603.3M | $234.8M | ||
| Q1 25 | $558.6M | $569.2M | ||
| Q4 24 | $536.6M | $359.0M | ||
| Q3 24 | $533.3M | $265.7M | ||
| Q2 24 | $528.1M | $209.9M |
| Q1 26 | — | $218.9M | ||
| Q4 25 | $135.1M | $122.5M | ||
| Q3 25 | $111.1M | $15.1M | ||
| Q2 25 | $90.3M | $-15.1M | ||
| Q1 25 | $114.6M | $204.3M | ||
| Q4 24 | $117.0M | $131.3M | ||
| Q3 24 | $96.4M | $91.1M | ||
| Q2 24 | $88.4M | $-11.6M |
| Q1 26 | — | 32.0% | ||
| Q4 25 | 21.6% | 40.6% | ||
| Q3 25 | 21.5% | 21.5% | ||
| Q2 25 | 20.9% | -0.5% | ||
| Q1 25 | 20.3% | 49.2% | ||
| Q4 24 | 23.4% | 52.8% | ||
| Q3 24 | 21.1% | 55.0% | ||
| Q2 24 | 19.9% | 2.8% |
| Q1 26 | — | 23.3% | ||
| Q4 25 | 19.1% | 27.8% | ||
| Q3 25 | 16.8% | 8.0% | ||
| Q2 25 | 15.0% | -6.4% | ||
| Q1 25 | 20.5% | 35.9% | ||
| Q4 24 | 21.8% | 36.6% | ||
| Q3 24 | 18.1% | 34.3% | ||
| Q2 24 | 16.7% | -5.5% |
| Q1 26 | — | $2.16 | ||
| Q4 25 | $4.65 | $1.21 | ||
| Q3 25 | $3.86 | $0.15 | ||
| Q2 25 | $3.10 | $-0.15 | ||
| Q1 25 | $3.67 | $2.02 | ||
| Q4 24 | $3.67 | $1.31 | ||
| Q3 24 | $3.01 | $0.91 | ||
| Q2 24 | $2.75 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | — |
| Total Assets | $2.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $497.0M | $2.4M | ||
| Q3 25 | $285.4M | $591.0K | ||
| Q2 25 | $46.3M | $931.0K | ||
| Q1 25 | $441.4M | $83.7M | ||
| Q4 24 | $669.4M | $1.9M | ||
| Q3 24 | $656.9M | $1.0M | ||
| Q2 24 | $510.9M | $22.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | $459.1M | $2.5B | ||
| Q3 25 | $293.6M | $2.4B | ||
| Q2 25 | $172.4M | $2.4B | ||
| Q1 25 | $593.6M | $2.5B | ||
| Q4 24 | $825.5M | $2.3B | ||
| Q3 24 | $881.4M | $2.2B | ||
| Q2 24 | $763.6M | $2.1B |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $7.9B | ||
| Q3 25 | $1.8B | $7.6B | ||
| Q2 25 | $1.6B | $7.3B | ||
| Q1 25 | $1.9B | $7.3B | ||
| Q4 24 | $2.1B | $7.2B | ||
| Q3 24 | $2.1B | $7.0B | ||
| Q2 24 | $1.9B | $6.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.32× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | 1.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $26.7M | ||
| Q3 25 | $246.2M | $81.2M | ||
| Q2 25 | $148.5M | $-28.9M | ||
| Q1 25 | $125.8M | $423.0M | ||
| Q4 24 | $190.7M | $-9.0M | ||
| Q3 24 | $149.1M | $64.5M | ||
| Q2 24 | $116.4M | $24.3M |
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 0.22× | ||
| Q3 25 | 2.22× | 5.39× | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | 2.07× | ||
| Q4 24 | 1.63× | -0.07× | ||
| Q3 24 | 1.55× | 0.71× | ||
| Q2 24 | 1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
NJR
| Utility | $640.9M | 68% |
| Nonutility | $298.5M | 32% |
